Drug Profile
PF 562271
Alternative Names: PF-00562271; PF-562,271Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Apr 2008 Pharmacokinetics data from a phase I trial in patients with Solid tumours presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
- 04 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
- 08 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section